NYSE - Nasdaq Real Time Price USD

Becton, Dickinson and Company (BDX)

Compare
233.50 -1.13 (-0.48%)
At close: September 20 at 4:00 PM EDT
230.00 -3.50 (-1.50%)
After hours: September 20 at 6:11 PM EDT
Loading Chart for BDX
DELL
  • Previous Close 234.63
  • Open 233.31
  • Bid 229.10 x 1000
  • Ask 234.02 x 800
  • Day's Range 231.53 - 234.19
  • 52 Week Range 218.75 - 269.52
  • Volume 1,973,750
  • Avg. Volume 1,364,995
  • Market Cap (intraday) 67.491B
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) 46.98
  • EPS (TTM) 4.97
  • Earnings Date Nov 7, 2024
  • Forward Dividend & Yield 3.80 (1.63%)
  • Ex-Dividend Date Sep 9, 2024
  • 1y Target Est 276.27

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

www.bd.com

70,000

Full Time Employees

September 30

Fiscal Year Ends

Recent News: BDX

View More

Performance Overview: BDX

Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BDX
3.07%
S&P 500
19.55%

1-Year Return

BDX
10.77%
S&P 500
28.32%

3-Year Return

BDX
4.49%
S&P 500
28.64%

5-Year Return

BDX
0.21%
S&P 500
89.66%

Compare To: BDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BDX

View More

Valuation Measures

Annual
As of 9/19/2024
  • Market Cap

    67.82B

  • Enterprise Value

    81.83B

  • Trailing P/E

    47.02

  • Forward P/E

    16.89

  • PEG Ratio (5yr expected)

    1.08

  • Price/Sales (ttm)

    3.45

  • Price/Book (mrq)

    2.62

  • Enterprise Value/Revenue

    4.13

  • Enterprise Value/EBITDA

    18.41

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.13%

  • Return on Assets (ttm)

    3.25%

  • Return on Equity (ttm)

    5.63%

  • Revenue (ttm)

    19.83B

  • Net Income Avi to Common (ttm)

    1.46B

  • Diluted EPS (ttm)

    4.97

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.31B

  • Total Debt/Equity (mrq)

    74.70%

  • Levered Free Cash Flow (ttm)

    4.43B

Research Analysis: BDX

View More

Company Insights: BDX

Research Reports: BDX

View More

People Also Watch